Donna Hallas discusses the Pfizer-BioNTech vaccine booster for children 5 to 11 years old

Article

Contemporary Pediatrics® Editorial Advisory Board member Donna Hallas shares her thoughts on the recent authorization of a Pfizer-BioNTech COVID-19 booster shot for children 5-11 years old.

In a video for Contemporary Pediatrics®, Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN, discussed the recent FDA amendment of the current emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine which is now authorizing a single booster dose for children 5-11 years old. The Booster will be available to children of this age at least 5 months after completing the primary vaccine series.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!
Recent Videos
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine
Tina Tan, MD, discusses impact of FDA's stricter COVID-19 vaccine policy for children
Jennifer Soung, MD reacts to FDA approval of roflumilast foam 0.3%
Related Content
Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis

Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis

Mercedes E. Gonzalez, MD
June 27th 2025
Article

Roflumilast cream 0.05% is being studied for mild-to-moderate AD in infants aged 3 months to under 2 years in a new phase 2 trial.

What's going on with polio, monkeypox, and COVID-19

What's going on with polio, monkeypox, and COVID-19

Miranda Hester
August 19th 2022
Podcast

The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?

ACIP updates: Committee votes 5-2 to recommend clesrovimab to protect against RSV | Image Credit: © JJHVEPhoto - © JHVEPhoto - stock.adobe.com.

ACIP updates: Committee recommends clesrovimab for RSV, reaffirms routine influenza vaccination

Joshua Fitch, Senior Editor
June 26th 2025
Article

The final recommendation sign off decision will go to HHS secretary Robert F. Kennedy Jr.

What Omicron could mean for the pandemic

What Omicron could mean for the pandemic

Miranda Hester
January 7th 2022
Podcast

Contemporary Pediatrics sat down with Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, to discuss what's known about the variant. She also discusses the latest on the vaccine for children aged younger than 5 years.

Donna Hallas

PNP Perspective: Focus on the positive outcomes of accepting vaccines

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN
June 25th 2025
Article

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, shares her thoughts on how PNPs can implement evidence-based strategies to encourage parents to vaccinate their children.

FDA approves at-home belimumab autoinjector for children with lupus nephritis |© Contemporary Pediatrics

FDA approves at-home belimumab autoinjector for children with lupus nephritis

Morgan Ebert, Managing Editor
June 24th 2025
Article

The FDA has approved belimumab (Benlysta; GSK) autoinjector for children with lupus nephritis, expanding at-home treatment.

© 2025 MJH Life Sciences

All rights reserved.